President Trump has thrown down the gauntlet, issuing a public ultimatum to 17 Big Pharma giants: lower your outrageous U.S. drug prices within 60 days, or brace for executive action that could finally force real accountability.
Story Snapshot
- Trump sends formal letters to 17 major pharmaceutical CEOs, demanding U.S. drug price cuts by September 29.
- Administration threatens further executive or regulatory action if companies refuse to comply.
- Some drugmakers signal willingness to negotiate, while industry stocks tumble on the news.
- Trump’s “Most-Favored-Nation” policy ties U.S. prices to those in other developed nations, aiming to end America footing the world’s drug bill.
Trump’s Ultimatum to Big Pharma: Lower Prices or Face the Heat
On July 31, 2025, President Donald Trump sent shockwaves through the pharmaceutical industry by delivering formal letters to the CEOs of 17 of the world’s largest drug companies. The message was blunt and simple: lower your prescription drug prices for Americans within 60 days, or the White House will intervene with executive or regulatory moves that could hit your bottom line hard. Trump’s administration, never shy about calling out corporate greed, went even further by publicly posting these letters, leaving no room for backroom deals or bureaucratic foot-dragging. The deadline? September 29. If these companies—names like Pfizer, Johnson & Johnson, AstraZeneca, and Eli Lilly—think they can ignore this, they’d better think again. Trump isn’t bluffing, and the American people are tired of being gouged at the pharmacy counter, subsidizing cheap drugs for Europe while paying two to three times more at home.
Trump sends 17 pharmaceutical companies letters calling for them to commit to lowering U.S. prescription drug prices https://t.co/mDCuNeW9xA
— One America News (@OANN) July 31, 2025
The administration’s “Most-Favored-Nation” pricing policy is at the heart of this push. It demands that U.S. consumers get the same fair deal as citizens in other developed countries—no more, no less. The letters were blasted out not just privately, but publicly, with a press briefing and a Truth Social post to ensure Big Pharma felt the political heat. Trump warned that any “failure to comply” would trigger executive action, a not-so-veiled threat that could include everything from price caps to importation of cheaper medicines. This isn’t just more talk; the administration has already signed an executive order to enforce this policy, making it clear that the era of endless excuses and blame-shifting from drug company lobbyists is over.
Background: America’s Raw Deal on Prescription Drugs
For decades, Americans have paid the highest prescription drug prices in the world, often two to three times what patients in Europe or Canada pay for the exact same medicines. Why? Because we’ve let globalist bureaucrats and corporate lobbyists set the rules, leaving our citizens to foot the bill for the rest of the world’s cheap meds. The U.S. accounts for 60% of global pharma revenue for American companies and up to 40% for foreign firms, all while our seniors and families struggle to afford basic prescriptions. Trump’s first term tried to tackle this with the same “Most-Favored-Nation” policy, but was stonewalled by industry lawsuits and a Congress that too often listens to donors, not voters. This time, with a clear executive mandate and a public that’s fed up, the stakes are even higher. The administration’s new order puts teeth behind the rhetoric, and the industry knows it.
The latest move comes after months of public outcry over runaway drug costs and after years of failed voluntary “discounts” and empty promises from pharma CEOs. The letters are a direct challenge to industry power, putting every company’s name on the line—and making sure the American people know exactly who’s standing in the way of lower prices. If these CEOs think they can hide behind complex pricing schemes or blame government red tape, Trump’s ultimatum exposes that game for what it is: corporate stonewalling at the expense of American families.
Industry Reaction: Denials, Excuses, and a Shaky Market
Big Pharma’s response was predictable—blame-shifting, vague promises, and a stock market tumble. Some companies, like Pfizer and Bristol Myers Squibb, announced token plans to lower prices on select drugs, hoping to take the heat off without committing to systemic change. Others resorted to the tired old playbook: warning about potential impacts on research and innovation, while quietly lobbying behind closed doors. The message from the White House was clear: “Most proposals my Administration has received…promised more of the same; shifting blame and requesting policy changes that would result in billions of dollars in handouts to industry.” Pharma stocks dropped 2–3% in the immediate aftermath, a sign that Wall Street knows this is more than just another policy skirmish—it’s an existential threat to business as usual.
The administration isn’t backing down. White House Press Secretary Karoline Leavitt emphasized that this is about transparency and accountability. The deadline is firm, and the American public will be watching to see which CEOs put patients ahead of profits. Some companies are already scrambling to negotiate, exploring direct-to-consumer models and price reductions for high-volume drugs. But as of August 1, not a single one of the 17 targeted companies has formally committed to bringing U.S. prices in line with international standards. The pressure is only going to build as the September 29 deadline looms.
